CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

Core Viewpoint - Cyclacel Pharmaceuticals, Inc. will implement a 1-for-16 reverse stock split effective May 12, 2025, with trading to begin on a split-adjusted basis on that day [1][2][3] Group 1: Reverse Stock Split Details - The reverse stock split will convert every 16 shares of common stock into one share, with no fractional shares issued; any resulting fractions will be rounded to the nearest whole number [2] - The board of directors and stockholders approved the reverse stock split, and a Certificate of Amendment will be filed with the Delaware Secretary of State [3] - The number of shares issued and outstanding will decrease from 356,357,531 to 22,272,346 post-split [3] Group 2: Company Overview - Cyclacel is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology [4] - The company is evaluating plogosertib, a PLK1 inhibitor, in patients with solid tumors and hematological malignancies as part of its epigenetic/anti-mitotic program [4] - Cyclacel aims to build a diversified biopharmaceutical business with a pipeline of novel drug candidates targeting oncology and hematology indications [4]